Business Context and Reporting Period
This Form 8-K was filed by EyeGate Pharmaceuticals, Inc. (trading symbol: EYEG) on January 5, 2021. The report details a material definitive agreement entered into on the same date regarding a private placement of equity securities. Note: The request metadata references "Kiora Pharmaceuticals Inc," but the filing text explicitly identifies the registrant as EyeGate Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
The filing describes a capital raise transaction rather than standard periodic financial results. Key metrics include:
- Securities Issued: 1,531,101 shares of common stock and warrants to purchase an equal number of shares (1,531,101).
- Purchase Price: $5.225 per share and warrant combined.
- Warrant Terms: Exercise price of $5.225 per share; exercisable starting six months after issuance; five-year term.
- Investor: Armistice Capital Master Fund, Ltd.
- Closing Date: Expected January 6, 2021, subject to customary conditions.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement and a Registration Rights Agreement. This transaction represents a dilution of existing shareholders through the issuance of new shares and warrants. The company is required to file a registration statement for the resale of these securities following the closing.
Outlook, Risks, and Unusual Items
Management Commentary: The company issued a press release on January 6, 2021, announcing the agreement. The transaction relies on exemptions under Section 4(a)(2) and Rule 506 of the Securities Act of 1933 as sales to accredited investors.
Risks and Contingencies: The filing includes standard disclaimers that representations and warranties in the Purchase Agreement are for the benefit of the parties and may not reflect the actual state of facts for stockholders. Information regarding the company's condition may change after the agreement date.
Investor Verification Checklist
- Verify the final closing of the private placement on or after January 6, 2021.
- Confirm the total gross proceeds raised based on the 1,531,101 units at $5.225 per unit.
- Review the filed Registration Rights Agreement (Exhibit 10.2) for specific timelines regarding the resale registration statement.
- Check subsequent filings for the impact of this issuance on the company's total outstanding share count and cash position.